NCT04401293View on ClinicalTrials.gov

Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

257

Participants

Timeline

Start Date

April 26, 2020

Primary Completion Date

May 14, 2021

Study Completion Date

May 14, 2021

Conditions
Sars-CoV2COVID
Interventions
DRUG

Enoxaparin

Full Dose LMWH anticoagulation therapy

DRUG

Prophylactic/Intermediate Dose Enoxaparin

Prophylactic/Intermediate Dose LMWH or UFH therapy

Trial Locations (6)

10075

Lenox Hill Hospital, New York

10309

Staten Island University Hospital, Staten Island

11040

Long Island Jewish Medical Center, Queens

11706

Southside Hospital, Bay Shore

11743

Huntington Hospital, Huntington

07112

Beth Israel Newark, Newark

Sponsors

Lead Sponsor

Northwell Health
All Listed Sponsors
lead

Northwell Health

OTHER